UPDATE: UBS Upgrades Eli Lilly (LLY) to Buy, New Top Pick
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/28/2023
- Wall St ends slightly higher after mixed Fed statements
- Charlie Munger dies at 99
- Barclays raises 2024 S&P 500 price target but warns stocks are 'moving too far, too fast'
- Stocks rise as dollar falls, gold rallies on Fed commentary
- Micron (MU) raises forecast on improved supply/demand balance and pricing
- Berkshire Hathaway (BRK.B): Charlie Munger has died
- BofA examines possible ArcelorMittal takeover of U.S. Steel
- Tesla (TSLA) exec releases Cybertruck event details
- Elliott Sends Letter to the Board of Crown Castle Inc. (CCI), Calls for Operational and Strategic Review of Fiber Business
- L3Harris Technologies (LHX) to Sell its Commercial Aviation Solutions Business to TJC for $800M
Eli Lilly & Co. (LLY) the 'Most Attractive Name' in UBS Large Cap Coverage
September 22, 2022 11:35 AM EDTUBS analyst Colin Bristow raised Eli Lilly's (NYSE: LLY) rating to Buy from Neutral, with its price target raised to $363 per share from $335.
Bristow explained, in a research note, they have been on the sidelines with LLY, primarily due to concerns around the risk-reward into... More
